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CONTEXT
MSF in Rwanda: towards HIV care
Médecins Sans Frontières (MSF) has been active in Rwanda since 1991. After the phase of 
emergencies (genocide, war), the programs were redirected towards support of the health 
districts and «intermittent» emergencies. By the end of the 90’s, the projects were reorien-
ted. In 2000, a mental health program was launched to provide psychological support to 3 
Kigali-based associations supporting women traumatized by war and genocide, often widows 
infected/affected by HIV. A HIV sensitization project in primary schools (Kigali, Cyangugu) was 
started the same year. Throughout these projects, it became clear that, in Rwanda at that time, 
the majority of activities in the ﬁeld of HIV/AIDS were directed towards prevention efforts. 
Two exploratory missions were done in 2000 and 2001, conﬁrming the lack of medical care 
for people living with HIV/AIDS (PLWHA) and drawing attention to the extent of the HIV epide-
mic (estimated prevalence rates of 16.3 % in Kigali, 19981). The active demands of the health 
authorities and various Rwandan HIV-associations to engage in the medical and psychosocial 
care of PLWHA, conﬁrmed the need to launch a HIV treatment program. Kigali was chosen for 
several reasons:    
>    High prevalence rates in certain sectors of Kigali with HIV being a major cause of mortality 
in Kigali
>  A network existed of community partners and local initiatives, requesting support 
>    The opportunity of a vertical program integrated into the existing functional health struc-
tures
A team consisting of a medical coordinator and a nurse were sent to Kigali in November 2001. 
The project was developed and formally approved by the national authorities by April 2002. 
With the decentralization (in 2002), further direct contacts with health authorities were mainly 
with the local administration.
 
Response towards HIV in Rwanda (at that time)
Though national programs against HIV were in place since the end of the eighties, the activi-
ties were obviously hampered during the years following the genocide and resulting national 
turmoil. Subsequently, the national program for HIV was given new life. The centralized ap-
proach, centered on the PNLS (Programme National de Lutte contre le SIDA) in the Ministry of 
Health, was modiﬁed in 1997 with decentralization and adoption of a multi-sectoral approach. 
In 2001, the PNLS was replaced by two separate national services: 
1  ANC sentinel surveillance data, TRAC 20033 3
>    the CNLS (Commission Nationale de Lutte contre le SIDA) was put in place, under the 
authority of the Presidency, mainly focusing on general policy, coordination and resource 
mobilization. Similar structures were organized at district and provincial level.
>    TRAC (Treatment and Research AIDS Center) was founded, under the authority of the 
Ministry of Health, and mainly working on medical and technical issues (guidelines, trai-
ning, monitoring) and surveillance.
The CNLS strategic plan for 2002-2006 emphasized the need to enhance HIV care and treat-
ment to individual patients including antiretroviral treatment (ART) and psychosocial care, and 
pointed out the need for partnerships, coordination and alignment of all activities within the 
multi-sectoral approach2. In 2003, a Ministerial instruction detailing the modalities of ART was 
published, ensuring free ART for the poorest. 
Since then, the combination of political commitment, well-functioning national services and 
the application of external ﬁnancial and technical support in a constructive way, have resulted 
in a fast scaling-up of various activities in the HIV ﬁeld, ranging from prevention to ART. The 
outcomes achieved in this MSF project reﬂect the favorable context of collaboration that has 
developed in Rwanda within the ﬁeld of HIV.
SCALING-UP OF ART WITHIN A HEALTH CENTER-
BASED PROGRAM 
The project was launched as a pilot program within a limited geographical region and with a 
close link to the community. It aimed to develop a model of care that was integrated within and 
adapted to the existing health structures, taking into account the lack of medical doctors in 
Rwanda at that time. The program was planned for 5 years, with potential extension to other 
parts of the country according to the needs. Building on the experience of MSF ARV programs 
launched since 2000-2001 in Kenya and South-Africa, the aim was to provide comprehensive 
care through a continuum of care, by providing medical and psychosocial care at various levels 
starting from the community level, towards health center (HC) and hospital level.  Access to 
care was a central issue, with the program mainly reaching out towards the most excluded 
and stigmatized people, and aiming to reduce barriers to their care. The scope of the program 
included IEC, VCT/PMTCT, counseling services and psychosocial support, family-planning, OI 
prophylaxis and treatment, hospitalization and ART. The whole package of care was provided 
free of charge. In addition to traditional prevention activities, the program hoped to have an 
indirect positive impact on prevention efforts by reducing the stigmatization of PLWHA and 
through IEC activities within the ART program, linked to the community.
2 CNLS Strategic Plan 2002-2006 (p83-87; p90-93)4 4
First phase: organizing care at the various levels 
(2002-2003) 
The HIV program started in April 2002 at three levels: with the Home Based Care (HBC) program, 
in two health centers (Kimironko and Muhima HC) and in Muhima district hospital. With the latter 
being transformed into a maternity service, Muhima HC was replaced by Kinyinya HC in 2003. 
1.  Community-based: home-based care program (HBC)
The objectives of the HBC program were to increase the access and quality of medical care for 
PLWHA in need and provide social support for and improve the quality of life of severely affec-
ted PLWHA. Nine HIV/AIDS associations, mainly working on solidarity and social issues, were 
selected to join the efforts. Volunteers were selected and trained in medical and psychosocial 
care of PLWHA. Through their knowledge of their area, bed-ridden people were approached, 
HIV-testing was discussed and medical care was provided with support of nurses on the ﬁeld. 
Severe cases were referred to the health centers or were given palliative care.  
The role of MSF in the HBC program was limited to
>  training of the volunteers and provision of basic equipment and incentives
>  organization and follow-up of medical activities through ﬁeld nurses
>  ensuring the  link to the health centers and care there
>  negotiating nutritional support (WFP)
>  capacity building of the associations: logistics; organization; material 
 
All PLWHA had the chance to join one of the associations, after which they got the support of 
a trained and supervised volunteer, providing regular visits at home. The volunteers provided 
domestic help, participated in basic daily nursing of patients, followed-up the adherence to 
treatment and gave psychosocial support to the patients and their families. 
The ﬁrst ﬁeld activities started in July 2002. By December 2004, around 120 volunteers were 
active, supported by 3 ﬁeld-nurses. Each volunteer followed between 4-10 people. From 2002 
to 2004, 1450 patients were reached through the associations, with 370 followed at home. 
The HBC-program has played an important role in ﬁghting isolation and stigmatization. The 
volunteers, serving as positive role-models of people living with HIV, helped to make HIV dis-
cussable within the community and to raise issues like testing of the partner and children.
With the roll-out of ART, the number of patients requiring palliative care diminished drama-
tically. As the capacity of the associations increased, MSF support was gradually reduced. It 
ended in 2004 and was redirected towards the health centers, where the launch of the ART 
program had signiﬁcantly increased the need for a psychosocial support program.5 5
Table 1. Chronogram of the HIV/ART program (2002-2007)
 
1. Organizing care at multiple levels (4/2002- 9/2003)
›  Home based-care program
›    Health center-based care: Kimironko Health center (KMK);  Muhima Health center (later 
on Kinyinya HC (KNN))
  •  Construction and rehabilitation works
  •  Launch of VCT/PMTCT and basic HIV care 
›  Hospital-based care: Muhima District hospital (KNN medical unit later on)
›  Psychosocial emphasis: collaboration with MSF mental health program
2. Introduction of Medical Care, ART and capacity building (10/ 2003-12/2004)
›  Launch of ART upon arrival of MD: KMK (10/2003); KNN (01/2004)
›  Capacity building:
  •  investment in nurse-based care (skills-building)
  •  building hospitalisation capacity in KNN
›  Psychosocial emphasis: 
  •  discussion and support groups in the HCs
  •  training on psychosocial impact of HIV (including children’s’ issues) 
3. Scaling-up (2005)
›  Involving nurses in care with continuous medical training and supervision
›  Launch of community support groups
›  Psychosocial emphasis: children psychosocial support program
4. Consolidation and increased autonomy of the HCs (2006-2007)
›  Further training for the entire health care staff
›  Addressing long-term issues of the ART program: toxicity, adherence,...
›  Training of HC staff in organizational aspects: stock-keeping, reporting,... 
›  Autonomy for community support groups
5. Hand-over of the project (2007)
 6 6
2.  Health-center based care: Kimironko and Kinyinya HCs
Kimironko HC is an urban state run health center with an catchment area of around 25 km2 
covering a population of about 75 000 people. Kinyinya HC is a semi-rural health center, loca-
ted at the outskirts of Kigali with a small local population.  
Initially, support was given by MSF-B to the health centers in terms of renovating and construc-
ting buildings, sponsoring the care and medications for the HIV positive patients and providing 
ﬁnancial incentives to the health-center staff. Training sessions for the nurses in diagnostic 
skills and treatment of OIs due to HIV were organized, and an HIV consultation process for OI 
prophylaxis and treatment was put in place. In collaboration with TRAC, the VCT and PMTCT 
services were launched. The activities in the HCs were aligned with the HBC and IEC activities. 
Overall, the ﬁrst phase of the program consisted of building the infrastructure and capacity 
within the HC to provide basic HIV care. 
3.  Hospital-based care 
With Muhima turned into maternity service for the CHUK, no district hospital existed in Kigali 
at that time. Given the urgent need for additional hospitalization capacity, activities were trans-
ferred from Muhima to Kinyinya health center, with the aim to transform it into an «upgraded» 
HC, accepting patients from the whole of Kigali, while awaiting the construction of the district 
hospital. This relatively large health center, that had been functioning as district hospital more 
than a decade before, was at that time only using 30 % of its operational capacity. Apart from 
the VCT/PMTCT and HIV care program, the capacity of KNN HC was expanded with 45 «medi-
cal» beds, a laboratory, an upgraded pharmacy and a medical doctor. On indication, transfer 
and follow-up of patients to the university hospital was organized.
4.  Political commitment
In this ﬁrst phase, basic care was organized within the existing (health) structures, in
close collaboration with the district health services. It is in this same period that the
strong political commitment at the national level towards HIV was evidenced, setting
the stage for the scaling-up of the national ART program. 7 7
Second phase: antiretroviral treatment  
and capacity-building (2003-2004)
By the end of 2003, an MSF doctor, later joined by a district doctor, was sent to each HC, to 
launch the ART program. From the onset, a strong emphasis was put on psychosocial support 
and treatment for children and pregnant women. A lot of time and energy was invested in theore-
tical and practical training, gradually training all staff in HIV care (see below). Responding to the 
increased work-load, the district services substantially increased stafﬁng at the health centers. 
Table 2. Support provided by MSF 
Logistics
›  construction, expansion and rehabilitation works
›  expansion of the laboratory service 
›  provision of transport (patients, samples, drugs)
›  expansion of the pharmacy: drugs and organizational support
›  accountancy services
›  data monitoring/reporting 
Training and supervision
›  nurse capacity building: theoretical and bed-side training
›  supervision and mentoring by the physician 
Psychosocial support
›  psychosocial team: psychologist/IEC responsible
  •  counseling caregivers and children
  •  support and discussion groups 
  •  individual psychological follow-up 
  •  training of staff on psychosocial support
›  nutritional support, community involvement
›  community support groups 
Financial/Human resources
›  ﬁnancial incentives for staff for extra work in training and scaling-up
›  training and increased involvement/responsibility
Collaboration 
›  negotiated support from World Food Program and the Global Fund
Technical support (national HIV program)
›  participation in technical working groups, workshops and conferences8 8
By the end of 2004, the antiretroviral program in the HCs was well-functioning, the hospita-
lization capacity had increased and a psychosocial support program was in place, including 
adult and children support and discussion groups. At that time, 5000 PLWHA had entered the 
program (KMK and KNN together) and 737 patients had been started on ART, 15.5 % of them 
children.  
Third phase: scaling-up of the ARV program (2005)
With the high number of patients in (urgent) need of ARV and the limited number of services 
available at the launch of the project, the program aimed for a rapid scaling-up, within a verti-
cal program. In 2005, the number of patients started on ART (in both HCs combined) increased 
to 119/month and by the end of the year 2089 patients received treatment (see Figure 1). As 
reﬂected in the mapping of the localization of our patients, Kinyinya was accessible for a large 
part of the city of Kigali (see Figure 2).
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Several factors have facilitated the scaling-up within a health-center based program:
Capacity building: capitalizing on nursing resources
The dramatically increased work-load during scaling-up implied increased involvement of 
nurses in providing HIV care. From the onset, skills-building of the (nursing) staff was em-
phasized. Ongoing training and supervision were provided by a combination of MoH and MSF 
physicians, who were ultimately responsible for the medical care. Nursing staff received theo-
retical and bed-side training in comprehensive HIV care and ART, gradually increasing their 
knowledge and conﬁdence. The approach towards managing side-effects of ARVs was stan-
dardized through basic protocols, and indications for referral to the physician were clariﬁed. 
As the program matured, physician involvement decreased gradually. Given the emphasis on 
psychosocial support and pediatric issues from the launch of the program, HC staff were sensi-
tized to these subjects at an early stage, and their skills improved through practical training.
Figure 2. Geographic distribution of patients on ART in KNN and KMK (2005)
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The increase in government health care staff at the health centers has been a critical factor to 
meet the increased demand. Whereas the KMK health center had 7 trained nurses before the 
launch of the HIV program in 2002, this had increased to 28 by the end of 2004, when scaling-
up began. Overall, around 40-50 % of the entire staff’s time was dedicated to HIV care. Table 
3 summarizes the stafﬁng (and who provided the salaries) for the HIV care program by 2005. 
Retention of the government staff was facilitated by performance-based ﬁnancial incentives, 
continuous training and promotion of responsibilities for the staff in the program. There was 
considerable energy and time spent on training and supervising the nurses, especially early 
in the program, but in our experience, this investment in capacity-building paid off in the end. 
When scaling-up began, the program was running smoothly and the role of the MSF team 
decreased gradually. 
Table 3. Human resources  for HIV care/health center (2005)1
HIV care service MoH  GF  MSF  Total
OI consultation (nursing staff) 3 3
ARV consultation (nursing staff) 2 2
Pharmacy ARV (nursing staff) 1 0.5 1.5
Pharmacy OI (nursing staff) 2 2
VCT/PMTCT/ANC (nursing staff) 4 4
Hospitalization (nursing staff) 2  2
Social assistant 2 1 3
Follow-up of referrals (nursing staff) 0.25 0.25
Psychologist 0.25 0.25
IEC 0.25 0.25
MSF MD 1 1
District MD 1 1
HIV lab-technician 0.25 1 1.25
Receptionist 2 2
Accountant 1 1
Data entry clerk 1 1
Total 16 3.25 6.25 25.50
1 With differences in HR between KNN and KMK HC, the numbers give an average estimate 11 11
Partnerships
Through the Global Fund to ﬁght AIDS, Tuberculosis and Malaria (GF), support was provided at 
various levels including construction work, contributions to the common basket for ARVs and 
CD4 counts, nutritional support, human resources and material. This funding helped subs-
tantially in scaling-up the activities in the HCs. The World Food program provided additional 
nutrition support for the PMTCT and ART program. The common basket system, launched at 
the end of 2004, further facilitated scaling-up activities of ART implementers. As mentioned 
above, the results within this program reﬂect the successful scaling-up of the national pro-
gram, with the support of all the different partners. 
Community-based support groups/Community involvement 
While the psychosocial support program was localized in the HCs when the ART program 
was started, this was gradually moved to the community by the launch of community support 
groups, leading to decreased work-load in the HC and engaging the community in care. The 
idea of these groups was for PLWHA to organize themselves into small groups, consisting of 
around 20 people living in the same area, promoting solidarity and breaking down discrimi-
nation and social isolation. In addition, this maintained a link with the community through the 
group leaders, identiﬁed by their colleagues. They were invited regularly to report on their 
activities, received continuing training and support and were involved in IEC and tracing of lost 
to follow- ups. 
Whereas it can be challenging to organize home-visits for all patients within a HIV program, 
these visits have played an important role to improve the individual care for PLWHA and to 
build links with the community. 
Fourth phase: solidifying the services  
and increasing autonomy (2006)
With the scaling-up of ART at the national level, the inﬂux of patients into the ART program 
in KNN and KMK gradually leveled off. During 2006, the services/activities were solidiﬁed and 
a strong emphasis was put on continuous training, aiming to have all the nurses trained in 
ART care and rotating through the different HIV services. This facilitated integration of the HIV 
program within the other health center services and sensitized the staff in all service areas 
to the HIV issues. This was a distinct advantage over having only a few specially-trained HIV 
nurses providing limited coverage. Speciﬁc attention was given to ongoing problems like long-
term toxicity and adherence. At the same time, the support provided by MSF could gradually 
be diminished and the HCs, linked with the newly built district hospital and supported through 12 12
the national program, gradually became more autonomous in all the aspects of the ART pro-
gram.
Table 4. Scaling-up of HIV services at the KMK and KNN health centers1
HIV program 2002  2003 2004 2005 2006
VCT
   Tested  1435 3187 6659 5754 5759
   % HIV+ 23.0 29.1 36.1 30.0 20.4
PMTCT
   Tested 1148 2458 3171 3727 3853
   % HIV+ 13.1 12.8 14.5 14.8 11.1
Consultation HIV
   Total 486 6814 33.569 45.609 39.100
   OI 486 6660 25.419  30.535 23.290
   ARV - 154 8150 15.047 15.810
Total on ARV - 58 733 2089 2970
1 Data for both health centers combined13 13
TREATMENT OUTCOMES OF THE PATIENTS ON ART
Between October 2003 and December 2006, 2970 patients received ART through KNN and 
KMK health centers. With data analyzed by July 2007, all patients had been on treatment for 
at least 6 months. 
Table 5. Characteristics of patients started on antiretroviral treatment (n=2970)
The baseline characteristics are described in Table 5. The median age at start was 35 years, 
69 % were female. The majority of patients were started with a WHO stage III/IV, and a median 
baseline CD4 count of 162 cells/µl. The generic ﬁxed-dose combination of d4T/3TC/NVP was 
Age at start (years) a 35 (29 – 41)
Sex (male/female) b 917/2053 (31/69)
Clinical WHO-stage (n=2957) b
    WHO stage I 193 (6.5%)
    WHO stage II 839 (28.4%)
    WHO stage III 1673 (56.6%)
    WHO stage IV 252 (8.5%)
Baseline weight in kg (n=2664) a 54 (46-60)
Baseline absolute CD4 counts (n= 2753) a 162 (94-231)
ART regimen b
    d4T/3TC/NVP 2467 (83.1%)
    d4T/3TC/EFV 223 (7.5%)
    AZT/3TC/NVP 199 (6.7%)
    AZT/3TC/EFV 63 (2.1%)
    Other  18 (0.6%)
Time on ART (years) b 1.8 (1.0-2.3)
a Values are expressed as median (Inter Quartile Range (IQR)
b Values are expressed as N (%)14 14
the most frequently used treatment regimen. The median time on ART was 1.8 years, with 
74 % taking ART for more than 1 year.
By July 2007, 2457 patients were still receiving treatment through the program. Two hun-
dred and eleven have been transferred out (7.1 %), 146 died (4.9 %). Overall, 156 patients 
(5.3 %) have been reported lost to follow-up, mainly patients previously receiving care in KNN.   
Kaplan-Meier analysis showed that 93.6 % were still alive at 3 years of ART. With failure deﬁ-
ned as death or lost to follow-up, 86.9 % of patients were still in care by 3 years (Table 6). Clear 
improvements in CD4 counts and weight were seen. Viral load was < 40 copies/ml and < 400 
copies/ml for 83.6 % and 89.4 % of the patients respectively. Currently, 19 patients have been 
started on second line therapy.
Table 6. Outcomes of the patients on ART
Whereas, in the early years of the program, very few patients were lost to follow-up, their num-
bers had increased signiﬁcantly from 2006 on (of all 156 patients lost to follow-up over the 4 
years, 68 % of these occurred in 2006-2007). Around 30 % of these were patients on treatment 
Started on ART Active cohort Transferred out Death Lost-to FU a
2970 (100 %) 2457 (82.7 %) 211 (7.1 %) 146 (4.9 %) 156 (5.3 %)
Baseline 6 mo 12 mo 24 mo 36 mo
Survival (%) b 100  97.1 96.1 95.0 93.6
In care (%) c 100 94.8 92.4 89.8 86.9
CD4 count (abs)  162 261 286 336 352
      IQR (94-231) (173-397) (185-435) (218-500) (210-559)
Weight gain (kg)   -  + 1.5 + 1.9 + 2.0 + 3.0
      IQR  - (-0.5;+3.6) (-0.8;+4.7) (-1.5;+5.4) (-1.0;+7.0)
Viral load  Months on ART  < 40 c/ml < 400 c/ml < 5000 c/ml
(N=1425)  17 (IQR 14-24) 1191 (83.6%) 1274 (89.4%) 1336 (93.7%)
 
a Deﬁned as not coming to their last scheduled visit for more than 2 months
b Kaplan-Meier survival estimates: failure deﬁned as death 
c Kaplan-Meier survival estimates: failure deﬁned as death or lost to follow-up15 15
for > 1 year, and had good clinical and immunological outcomes, making mortality as reason 
for lost to follow-up less likely. Feed-back from the community support group leaders point out 
that a substantial number are still under care, but have moved to another center, often closer 
to home. However, 43 % of all patients lost to follow-up were on ART for < 6 months. Since the 
ﬁrst few months on ART have a relatively high mortality rate, a certain number of these cases 
can be expected to be unreported deaths.
 
Toxicity of the stavudine-based ﬁrst line ARV 
regimens
With the high number of patients started on a stavudine-containing regimen, the assessment 
of long-term complications of ART was part of the routine medical follow-up. A standardized 
approach was developed for diagnosis and management of mitochondrial toxicities (sympto-
matic hyperlactatemia/lactic acidosis (SH/LA), lipoatrophy and neuropathy)
Table 7.   Severe toxicity with d4T and/or nevirapine-containing  
ﬁrst-line regimens
Drug related toxicity Events   
(%)
Rate 
/1000 py
Patients with toxicity-related drug substitution (%) b 
Nevirapine  (n=2667) 6 mo 12 mo 24 mo 36 mo
Toxicity all 170 (6.4) 39 6.0 6.4 6.9 7.2
Skin toxicity 131 (4.9) 30 4.9 5.1 5.3 5.4
Liver toxicity 40 (1.5) 9 1.1 1.3 1.6 1.8
Stavudine (n=2694)
Toxicity all 448 (16.6) 107 2.6 8.6 22.5 35.4
Neuropathy 206 (7.6) 49 2.3 6.0 9.8 12.1
SH/LA a 85 (3.2) 20 0.2 2.0 4.5 6.0
Lipoatrophy (La)  180 (6.7) 43 0.0 1.0 9.2 19.8
SH/LA and/or La 248 (9.2) 59 0.3 2.6 12.9 24.2
a Symptomatic Hyperlactatemia/Lactic Acidosis
b Kaplan-Meier estimates, time to ﬁrst severe toxicity (ie requiring treatment change) at speciﬁed months on ART16 16
Of the 2694 patients that started on a d4T-containing ﬁrst line regimen, therapy was changed 
due to d4T-related toxicity for 448 patients (16.6 %). In total, 7.6 % of the 2694 patients changed 
for severe neuropathy, 3.2 % for lactic acidosis and 9.2 % for moderate/severe lipoatrophy. 
Whereas in the ﬁrst year therapy changes were mainly due to neuropathy, lipoatrophy was the 
most frequent long-term side-effect (Figure 3). 
Nevirapine-related toxicity was less frequently seen, mostly occurring within the ﬁrst months 
on ART. For the 2667 patients starting on a nevirapine-containing regimen, therapy was chan-
ged due to NVP-related toxicity for 170 patients (6.4 %), mainly presenting with skin toxicity 
(Table 7). 
Monitoring ART: discordant treatment responses
Whereas on average the CD4 count increases when viral replication is inhibited by ART (and 
vice versa), considerable variability at the individual level has been documented. In particular, 
discordant responses (ie opposite immunological and virological responses) have been fre-
quently observed, both in high and low-income countries. 
Most of the viral load results came from adult patients. With virological success deﬁned as a 
viral load < 40 copies/ml (> 1 year on ART) and immunological success as an increase in CD4 
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Figure 3. Substitution of stavudine due to drug toxicity
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count > 50 cells/ml from baseline at the time of viral load measurement, we observed combi-
ned immunological and virological success in 65.6 % of cases and combined failure in 4.7 % of 
the adult patients (concordant responses), see Table 8. Twelve percent of all adult patients had 
immunological success despite a detectable viral load. Importantly, virological suppression 
(success) without immunological recovery was seen in 17.7 % of patients (discordant respon-
ses in 29.7 %). This type of treatment response has been frequently observed in both high and 
low-income countries and remains poorly understood. With virological success deﬁned as a 
viral load < 1000 copies/ml, discordant responses were still seen in 24.7 %. Interestingly, the 
CD4 response for children on ART differed to some extent: almost all showed an increase in 
CD4 count, even when having active viral replication. 
Table 8. Virological-immunological outcomes on ARV treatment (n(%)) 1
The frequent occurrence of discordant responses illustrates the limitations of the CD4 count 
for monitoring the treatment response. If no viral load testing had been available, a large 
number of patients with immunological failure, despite virological success, might have been 
started on second-line ART incorrectly. In contrast, since there is no other proven strategy to 
enhance immune recovery and these patients are considered to have a relatively favorable 
prognosis despite the limited immune recovery, they should be continued on their current 
regimen. On the other hand, some patients have a steady increase in CD4 count despite a de-
tectable viral load. They run the risk of developing and transmitting drug-resistant virus.   
                                              ADULTS                            CHILDREN
Threshold  VL < 40 VL ≥ 40   VL < 40   VL ≥ 40 Total
Immunological 
success  661 (65.6) 121 (12.0)   95 (68.8)   32 (23.2) 909 (79.4) 
Immunological 
failure 178 (17.7)  47 (4.7)   7 (5.1)   4 (2.9) 236 (21.6)
Total 839 (83.3) 168 (16.7)   102 (73.9)   36 (26.1) 1145 (100)
1 Viral load was routinely performed after at least 1 year of ART18 18
PROVIDING ANTIRETROVIRAL TREATMENT  
FOR CHILDREN
By the end of 2006, 315 children (≤ 15 years) had been started on HAART, constituting 11 % of 
the total ARV cohort. With a very low rate of mortality and lost to follow-up, the overall outco-
mes are even better than for adults. 
Psychosocial support as key to successful ART-scaling up for children 
Since 2000, the MSF mental health program in Rwanda had been working with women who 
were victims of violence during the genocide. A substantial number of them were HIV-infec-
ted, and so the issue of HIV infection in their children with associated problems of testing and 
disclosure was well known by the team. The need to address psychosocial issues in HIV care 
resulted in a collaboration between the mental health team and the HIV program. We believe 
that this focus on psychosocial issues for PLWHA in general and for children in particular from 
the onset of the program has been a key factor for the successful scaling up of the paediatric 
HIV/ARV program (Table 9). By gradually adapting over the years to the problems encountered 
within the program, the current psychosocial program for children took form and several les-
sons were learned. 
 VCT for children: overcoming barriers by addressing the psychosocial needs of caregivers
From the onset, the need of the patients to express themselves on issues concerning HIV was 
evident. Caregivers themselves were distressed by their own (recent) HIV diagnosis. They were 
reluctant to discuss testing of their children, since they felt guilty, fearing the reaction of the 
child to their own and the child’s disclosure, and being worried about the health and future of 
the child. From the start of the program, support and discussion groups were organized for 
the caregivers, designed to increase acceptance of their own HIV positive status, a prerequisite 
for discussing testing of their children. In addition, prior to starting ARVs, individual in-depth 
counseling sessions were held to discuss testing of children in detail. Subsequently, the health 
center-based support groups were transformed into community-based support groups, within 
which issues like testing of partners and children were discussed amongst peers.19 19
Table 9. Psychosocial aspects of the pediatric HIV program
 
   Caregiver-centered approaches
› organization of discussion/support groups – at health center and in community
› family-based approach to identify eligible children
› individual counseling (pre-ART)
› psychosocial issues addressed in follow up care
   Child-centered approaches
› adapted counseling for children for disclosure and ART (child-adapted tool)
› designated days for children’s clinics
› child support groups
› integrated care, including disclosure, with their caregivers
   Health-staff centered approaches
› discussion groups for health care staff
› training on psychosocial implications of HIV 
› practical training by psychosocial team (check-lists,...)
› supervision and mentoring
 
Building conﬁdence: training  health care staff on child-speciﬁc issues of HIV
Early in the program, several barriers were observed for the medical staff to test children, 
essentially related to a ‘fear of the result’. There seemed to be a lack of conﬁdence and skills 
in discussing an HIV-positive test with the parents and the children. Consequently, training 
sessions were organized for the medical staff. Apart from formal training on counselling and 
the psychosocial aspects of HIV in general, discussions with the health care staff were orga-
nised to address the issue of testing of children (why, when, how?). Through these sessions 
and discussions, medical staff progressively felt more convinced of the need and conﬁdent in 
how to test children of HIV-positive adults. 20 20
Adequate disclosure: prerequisite for good adherence
In our experience, adults and children were generally not well prepared when they came for 
testing of the child. Few children knew exactly why they were there, had little knowledge of 
HIV and rarely knew about the status of the caregiver. However, the children preferred to be 
informed about their and their caretaker’s status from the caretaker and felt cheated when 
they were not told the truth. Consequently, we tried to involve the caretaker as much as possi-
ble during disclosure. Caretakers were ﬁrst counselled on why it was important to talk openly 
with their children about HIV, why their active participation was important for the child, how 
the child might react, and how they should respond to questions. During disclosure, we tried 
to have the caregiver explain their and the child’s status, supported by the counsellor. The use 
of a booklet explaining HIV provided a common language around HIV (Figure 4). 
     
Figure 4. Picture from the tool used to explain HIV/AIDS to children. 
The CD4 cells (umbrellas) protect against the rain (diseases).
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Testing of children was done on a separate day, ensuring that enough time was available for 
every child, making the environment/event more child-friendly and facilitating on-site training 
of health care staff in counseling of children. Individual disclosure was considered when the 
child was above 6 years of age.
Children support groups - active involvement of the children
To increase the acceptance of the HIV diagnosis and to address the psychosocial well-being 
of the children after testing, support groups for children were organized by the psychosocial 
team. These groups created an environment where the children could express themselves, 
raise their questions and worries and develop a positive attitude towards life with HIV. Most 
of the issues discussed were raised by the children themselves and reﬂected their deeper 
feelings: HIV (what, why and how?), life and death, sexuality, manipulation in the parent-child 
relationship and discrimination. This was done in several ways including open discussions, 
games, fairy-tales and drawings
For the time being, around 18 groups with 200 children have been organized, meeting every 
4-6 weeks. These groups were open to all children, irrespective of taking ART, and were or-
ganized according to age (7-11; 12-14; 15-18). Caregivers were invited to participate in some 
of these sessions to ensure they were aware of the children’s knowledge and feelings towards 
their diagnosis. If individual problems were identiﬁed through the groups, individual follow-up 
was offered.  More recently, the child support groups were combined with the medical consul-
tation, while at the same time a support group for caretakers was taking place.
© Julie Rémy22 22
Treatment outcomes of the children on ART 
Over a period of more than 3 years, 315 children were started on ARVs, with a median age of 
7.2 years (Table 10).
Table 10. Characteristics of children started on antiretroviral  
treatment (n=315)
 Age at start a  7.2 (4.5 – 10.4)
     < 3 years b  38 (12%)
     3 – 4.9 years b  51 (16%)
     5 – 14.9 years b  226 (72%)
 Sex (male/female) b  157/158 (50/50%)
 Clinical WHO-stage b
     WHO stage I  43 (13.7%)
     WHO stage II  145 (46.0%)
     WHO stage III  115 (36.5%)
     WHO stage IV  12 (3.8%)
 Weight for age (z-score) (n=293) a  -1.9 (-3.0;-0.9)
Baseline CD4 count % (n=282) a  14% (9-18)
     < 15 % b  158 (56.0%)
     15-25 % b  118 (42%)
     > 25 % b  6 (2.1%)
Baseline absolute CD4 counts (n= 302) a  345 (229-572)
 ART regimen b  
     d4T/3TC/NVP  281 (89.2%)
     d4T/3TC/EFV  6 (1.9%)
     AZT/3TC/NVP  19  (6.0%)
     AZT/3TC/EFV  9 (2.9%)
 Time on ART (years) a  2.0 (1.2-2.6)
a Values are expressed as median (Inter Quartile Range (IQR)) 
b Values are expressed as N (%)23 23
Approximately 25 % were less than 5 years of age, 7 were started before the age of 18 months. 
Sixty-one percent were in WHO stages I and II at treatment initiation with a median baseline 
CD4 count of 14 %. The vast majority started on d4T/3TC/NVP, with adult FDC tablets used for 
282 children. The remaining 33 commenced syrup formulation. By the time of analysis, all but 
ﬁve had changed to tablets. The median time on ART was 2 years. 
Clinical, immunological and virological outcomes (Table 11)
To date, 84 % (265) are still alive and being followed up in the clinics. Thirty (9.5 %) have been 
transferred to another ART program. Eight (2.6 %) have died, only 12 (3.8 %) were lost to fol-
low-up. Of the 8 deaths, 2 were clearly not linked to HIV. Kaplan-Meier estimates showed a 
probability of remaining in care of 94.7 % and 92.9 % at 12 and 24 months respectively (with 
failure deﬁned as death or lost-to follow-up). CD4 results and the Weight-for-age Z-scores 
(WAZ) all showed progressive improvement over the treatment interval. Most viral load re-
sults were obtained between and 15 and 23 months after treatment commencement and were 
available for 88 % by 18 months  (n=174). Viral load was less then < 400 copies/ml in 82.8 % of 
children and showed satisfactory viral suppression in 86.8 %.
Table 11.  Clinical, immunological and virological outcomes
Started on ART Active cohort Transferred out Death Lost-to follow up a
315 (100 %)   265 (84.1 %) 30 (9.5 %) 8 (2.6 %) 12 (3.8 %)
Baseline 6 mo 12 mo 24 mo 36 mo
   Survival (%) b 100  96.8 94.7 92.9 92.9
       N 315 297 258 152 40
   CD4 count 
   < 5 years (%) 16 30 32 33 35
       IQR (12-19) (23-35) (26-34) (28-36) (28-40)
       N 84 59 48 39 7
    ≥ 5 years (%)  13  25  26 29 29
       IQR (9-17)  (18-29) (21-32) (24-34) (19-33)
       N 198 175 117 80 24
    WAZ   -1.9  -1.6 -1.6 -1.5 -1.5
       IQR  (-3.0;-0.9) (-2.6;-0.8) (-2.6;-0.7) (-2.5;-0.6) (-2.7;-0.6)
Viral load  Months on ART               < 40 c/ml               < 400 c/ml               < 5000 c/ml
18 (15-23)                        127 (73.0%)              144 (82.8%)               151 (86.8%) (N=174) 
a Deﬁned as not coming to their last scheduled visit for more than 2 months
b Kaplan-Meier survival estimates: failure deﬁned as death or lost-to follow-up24 24
For 13 children among whom viral loads were detectable, a second sample was available after 
adherence counseling. The median time from ﬁrst viral load collection to the repeat sample 
was 5.8 months (IQR 2.7-8.8). Four out of the 13 positive viral loads became undetectable and 
one decreased signiﬁcantly. Two children were switched to second line treatment. For the 
remaining children, adherence problems were still being addressed or criteria to switch were 
not met.
We only had complete data on clinical attendance as an indirect measure of adherence to 
therapy. Allowing a delay of up to two days (accounting for the security stock), we deﬁned ex-
cellent, good and poor adherence as being punctual for > 95 %, 80-95 % or < 80 % of the visits 
respectively. Poor adherence was observed for 5 % of the children, with the majority having 
excellent (49 %) or good (46 %) adherence. 
Safety and tolerance
Drug toxicity resulted in therapy changes for 26 children (8.3 %). Toxicity was mainly related 
to NVP, requiring treatment change to EFV (n=24). Sixteen cases were due to grade 3-4 skin 
manifestations of which two were Stevens-Johnson syndrome occurring within 1 month of 
therapy. Both have recovered. Five early changes (within 3 months) were made for severe 
hepatitis, 4 children showing clinical signs, 1 child having asymptomatic grade 3 hepatotoxi-
city. An additional three children were changed late (median 9 months) due to symptomatic 
hepatitis. We observed an additional 11 children with grade 2 and 3 with grade 3 liver toxicities, 
mostly occurring within the ﬁrst months of ART. In general, these were transient and well 
tolerated and did not require treatment change. Stavudine was changed for one child with 
severe neuropathy; two cases of lipoatrophy were reported (one requiring treatment change). 
No lactic acidosis or anemia requiring treatment change was observed. In contrast, a high 
occurrence of lactic acidosis and lipoatrophy was observed within the adult population.
CONCLUSION AND LESSONS LEARNED
This program offers reassuring evidence that health center-based ART programs can provide 
high quality care and suggests a way forward in scaling up ARV treatment. A combination of 
factors has probably contributed to the overall good outcomes of the program. 
The localization in health centers and the link with the community has facilitated access and 
acceptability of testing and care. In addition, the program aimed to minimize barriers to care 
and to address the various needs of PLWHA by providing free comprehensive medical care 
(including nutritional support and OI treatment and prophylaxis) and through a strong psy-
chosocial emphasis within a family-based approach. The community has progressively played 
an increased role in IEC activities, adherence and psychosocial support. A lot of energy was 
put into training and mentoring of the nursing staff, however, this allowed fast scaling-up to 25 25
occur and facilitated integration of the HIV care program into the health center services.  This 
experience shows that an ART program relying extensively on trained nurses can maintain 
excellent outcomes during scaling-up, given investment in human resources, training and su-
pervision. 
The combination of all these factors also helps to explain the high number of children being tes-
ted and their overall good treatment outcomes. This experience shows that providing pediatric 
ART within a health-center based program can be very effective and safe. It also demonstrates 
that there is a signiﬁcant burden of HIV illness in children, besides that from PMTCT sources, 
that is readily identiﬁable through their HIV+ caregivers, given a program that makes it a goal. 
This requires that psychosocial support programs, addressing both the needs of the children 
and caregivers, are considered an essential part of HIV/ART programs.
We think that this kind of program could be replicated in other settings and is sustainable. The 
success of the program depended, to a large extent, on the commitment of the national servi-
ces and the success of the national HIV program. External support of this HC-based program 
by MSF was targeted at certain areas such as logistics, training and psychosocial support. This 
support decreased gradually over the last year, with standards of care remaining high and 
MSF is handing over the project to the Ministry of Health at the end of 2007.
MAJOR REMAINING CHALLENGES
1.    Although excellent clinical and immunological responses have been observed on current 
WHO ﬁrst-line regimens, the stavudine-based regimens are associated with important 
toxicity. This could limit the future success of these regimens and calls for better tolerated 
ones. 
2.    A signiﬁcant number of patients can be expected to experience treatment failure within 
the near future, pointing out the need for a widely available, affordable and well-tolerated 
second-line therapy.  Access to viral load testing is important to correctly decide on the 
need for second-line treatment.  
3.    Long-term adherence and acceptance problems can be expected (in particular for adoles-
cents), calling for close follow-up and a pro-active approach.
4.  The long-term success of this program will require (amongst others) several factors:
  a.  long-term political commitment 
  b.  ongoing ﬁnancial resources and investment in human resources
  c.  continuous and increasing community involvement 
  d.  low barriers of access to care
  e.  strong focus on the psychosocial aspects of HIV 
  f.  special attention/support for children26
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